DOXIFLURIDINE

/static/temp/default.svg

Search structure


Synonyms	5'-Deoxy-5-Fluorouridine Capecitabine related compound b Doxifluridine Flutron Fulturon Furtulon NSC-758890 RO 219738 RO-219738
Status
Molecule Category	UNKNOWN
UNII	V1JK16Y2JP
EPA CompTox	DTXSID2022967


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	ZWAOHEXOSAUJHY-ZIYNGMLESA-N
Smiles	C[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O
InChI	InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C9H11FN2O5
Molecular Weight	246.19
AlogP	-1.69
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	1.0
Polar Surface Area	104.55
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	17.0

Bioactivity

Mechanism of Action	Action	Reference
DNA disrupting agent	DISRUPTING AGENT	FDA PubMed


Protein: Thymidylate synthase Description: Thymidylate synthase Organism : Homo sapiens P04818 ENSG00000176890

Assay Description	Organism	Bioactivity	Reference
Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 125 mg/kg orally on day 20	Mus musculus	18.0 %
Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 250 mg/kg orally on day 20	Mus musculus	15.0 %
Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 500 mg/kg orally on day 20	Mus musculus	19.0 %
Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 62.5 mg/kg orally on day 20	Mus musculus	8.0 %
Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 750 mg/kg orally on day 20	Mus musculus	50.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	-5.06 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	24.16 %		SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	30.34 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.03 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.01 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.01 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.03 %

Related Entries

Cross References

Resources	Reference
ChEBI	31521
ChEMBL	CHEMBL1130
DrugBank	DB12947
DrugCentral	958
FDA SRS	V1JK16Y2JP
Human Metabolome Database	HMDB0060406
KEGG	C12739
PubChem	18343
SureChEMBL	SCHEMBL8094
ZINC	ZINC000001319177

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).